LINC00886 drives ovarian cancer progression and immune escape through themiR-423-5p/TLR4/Myd88/NF-κB/PD-L1 axis, establishing its potential as both a prognostic biomarker and therapeutic target. This evidence concerns the gene NFKB1 and ovarian carcinoma.